We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO International ConventionJune 3-6, 2019
BIO World Congress on Industrial Biotechnology and Ag TechJuly 8-11, 2019
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
February 11 - 12, 2019 | New York, New York
EyeGate is a clinical-stage specialty pharmaceutical company developing and commercializing products for treating diseases and disorders of the eye. The Company has two proprietary platform technologies.
Our most advanced platform is based on cross-linked thiolated carboxymethyl hyaluronic acid (“CMHA-S”), a modified form of the natural polymer hyaluronic acid (“HA”), which is a gel that possesses unique physical and chemical properties such as hydrating and healing when applied to the ocular surface. We recently announced positive data from two studies for our lead CMHA-S product, EyeGate Ocular Bandage Gel (“OBG”), which is being developed for corneal re-epithelialization following photorefractive keratectomy (“PRK”) surgery, as well as for better management of patients with punctate epitheliopathies (“PE”) due to pathologies such as dry. EyeGate OBG is classified as a Class 2 medical device, which we plan to pursue U.S. regulatory clearance via the FDA’s De Novo 510(k) pathway.